News about "Trastuzumab Deruxtecan"

Enhertu Plus Pertuzumab Approved in China for First-Line HER2-Positive Metastatic Breast Cancer

Enhertu plus pertuzumab has been approved in China as first-line treatment for HER2-positive metastatic breast cancer, based on positive phase 3 results.

Trastuzumab Deruxtecan | 13/08/2026 | By News Bureau |  101

EMA Committee Recommends Approval of AstraZeneca and Daiichi Sankyo's Enhertu Plus Pertuzumab

If approved, AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab would become first new treatment in the European Union (EU) in more than a decade for first-line HER2-positive metastatic breast cancer.

Trastuzumab Deruxtecan | 25/07/2026 | By News Bureau

CDSCO Approves AstraZeneca's Trastuzumab Deruxtecan Plus Pertuzumab Combination

AstraZeneca Pharma India has received CDSCO approval for trastuzumab deruxtecan plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.

Trastuzumab Deruxtecan | 12/06/2026 | By News Bureau |  103

US FDA Approves Enhertu for New Early Breast Cancer Indications

Enhertu receives new US approvals for use before and after surgery in HER2-positive breast cancer, supported by positive DESTINY-Breast11 and DESTINY-Breast05 phase 3 trial results.

Trastuzumab Deruxtecan | 18/05/2026 | By News Bureau |  160

PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan

Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.

Trastuzumab Deruxtecan | 25/03/2026 | By News Bureau |  350

AstraZeneca India to Launch Hyperkalaemia Treatment Lokelma in November 2025

AstraZeneca Pharma India Limited (AZPIL) has announced the upcoming launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in India in November 2025.

Trastuzumab Deruxtecan | 15/10/2025 | By Dineshwori |  1189

Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer

Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />

Trastuzumab Deruxtecan | 08/10/2025 | By Dineshwori |  571

CDSCO approves AstraZeneca's Trastuzumab Deruxtecan for More HER2-Positive Tumours

With this, Trastuzumab Deruxtecan becomes India’s first Antibody Drug Conjugate (ADC) approved for a tumour-agnostic indication.

Trastuzumab Deruxtecan | 04/10/2025 | By Dineshwori |  335

US FDA Grants Priority Review for Enhertu + Pertuzumab in HER2+ Metastatic Breast Cancer

The US FDA has granted Priority Review to Enhertu + Pertuzumab for HER2+ metastatic breast cancer, following DESTINY-Breast09 trial results showing a 44 percent reduction in risk of disease progression or death and over three years’ median Progression-Free Survival (PFS), positioning it as a potential new first-line standard of care.

Trastuzumab Deruxtecan | 25/09/2025 | By Dineshwori |  210